secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0000950170-23-013165
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD
--------------------------------------------------------------------------------

- Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.
- Primary outcome: mean change in BCVA from baseline to Week 36; secondary include CST and treatment burden.
- CLS-AX arm: 3 aflibercept loading doses + CLS-AX at baseline, then at least every 24 weeks.
- Enrollment starts Q2 2023; topline results expected in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/0000950170-23-013165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023013165/clsd-20230418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer